{"id":"W2023078169","doi":"10.1002/ibd.21896","title":"Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study","year":2011,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":207,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University; London Health Sciences Centre","funders":"Takeda Oncology","keywords":"Vedolizumab; Ulcerative colitis; Medicine; Tolerability; Pharmacokinetics; Pharmacodynamics; Internal medicine; Gastroenterology; Crohn's disease; Pharmacology; Adverse effect; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003779799,0.001558373,0.003736613,0.000611144,0.0004665785,0.001295559,0.001058296,0.001880465,0.005312674],"category_scores_gemma":[0.002088869,0.0008254707,0.001902099,0.0006040213,0.001325151,0.001202451,0.0004056733,0.00268614,0.0008945228],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006965804,"about_ca_system_score_gemma":0.001127308,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004657306,"about_ca_topic_score_gemma":0.0009555893,"domain_scores_codex":[0.9986388,0.0007530033,0.00008760264,0.0002115947,0.0001400118,0.0001689515],"domain_scores_gemma":[0.9985208,0.0004124623,0.0003734779,0.0001598373,0.0001435588,0.0003898203],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9613791,0.01624949,0.0007222138,0.0006187926,0.000915098,0.00004443109,0.0000471551,0.0002816832,0.004946265,0.00005744911,0.0004586167,0.01427975],"study_design_scores_gemma":[0.9183307,0.07837968,0.001867737,0.00002066779,0.0003115457,0.00002929411,0.000008852178,0.0002014218,0.0003221973,0.00003856217,0.0004789494,0.00001046799],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9768413,0.007149231,0.00136197,0.0006404359,0.0004616051,0.01053771,0.001221086,0.0001949032,0.001591683],"genre_scores_gemma":[0.9716089,0.00567857,0.003533923,0.001873527,0.0009222104,0.0115278,0.00174399,0.00005324566,0.003057848],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005312674,"threshold_uncertainty_score":0.01998973,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01539788876544992,"score_gpt":0.2767287282332005,"score_spread":0.2613308394677506,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}